On August 24, Moderna, Inc. declined 5.65% in regular trading, trading at $134.49/share, with turnover of $490 million. The stock remains in a highly volatile repricing phase following its historic 177% single-day surge earlier in the week.

The ongoing volatility traces back to August 19, when Moderna and Merck jointly announced that their personalized mRNA cancer vaccine intismeran autogene achieved primary and secondary endpoints in the Phase III INTerpath-001 trial for high-risk melanoma patients. The breakthrough triggered a $44 billion market cap addition in a single session. However, the stock subsequently pulled back 23.5% on profit-taking, rebounded 16%, and continues to oscillate as the market digests the implications.

Wall Street has broadly re-rated the stock: Barclays raised its target from $48 to $125, JPMorgan from $40 to $77, Goldman Sachs from $67 to $120, BofA from $40 to $170, and Piper Sandler from $77 to $167. The consensus mean target now stands at $96.47. Options implied volatility remains at the 99.6th percentile, reflecting persistent uncertainty around fair value. UBS reported clients net-sold $44 million of Moderna shares on the day of the initial surge, and short sellers faced approximately $4.8 billion in mark-to-market losses.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)